Tower Research Capital LLC (Trc) E Ffector Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.37 - $0.69 $4,131 - $7,704	-11,166 Reduced 90.53%	1,168 $0
Q3 2023 Nov 14, 2023	BUY	$0.49 - $0.88 $955 - $1,715	1,949 Added 18.77%	12,334 $7,000
Q2 2023 Aug 14, 2023	BUY	$0.35 - $1.39 $24 - $95	69 Added 0.67%	10,385 $8,000
Q1 2023 May 09, 2023	SELL	$0.35 - $0.67 $4,344 - $8,316	-12,412 Reduced 54.61%	10,316 $4,000
Q4 2022 Feb 10, 2023	BUY	$0.38 - $0.66 $2,401 - $4,171	6,321 Added 38.53%	22,728 $10,000
Q3 2022 Nov 10, 2022	BUY	$0.08 - $1.41 $714 - $12,589	8,929 Added 119.4%	16,407 $9,000
Q2 2022 Aug 15, 2022	BUY	$1.3 - $3.84 $9,009 - $26,611	6,930 Added 1264.6%	7,478 $11,000
Q1 2022 May 12, 2022	SELL	$3.85 - $8.2 $727 - $1,549	-189 Reduced 25.64%	548 $2,000
Q4 2021 Feb 14, 2022	SELL	$5.71 - $13.15 $34,956 - $80,504	-6,122 Reduced 89.25%	737 $7,000
Q3 2021 Nov 15, 2021	BUY	$8.56 - $27.17 $58,713 - $186,359	6,859 New	6,859 $97,000

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.